ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: A study of 180 homozygotes for the Factor V Leiden mutation

British Journal of Haematology

Volumn 135, Issue 5, 2006, Pages 697-702

  Biron Andreani, C ^a   Morange, P E ^b   Le Cam Duchez, Véronique ^c   Borg, Jeanne Yvonne ^c   Saladin Thiron, Catherine ^c   Bauters, Anne ^c   Jude, Brigitte ^c   Morange, Pierre Emmanuel ^c   Aillaud, Marie Françoise ^c   Juhan Vague, Irène ^c   Biron Andréani, Christine ^c   Schved, Jean François ^c   Vergnes, Christine ^c   Pernod, Gilles ^c   Polack, Benoit ^c   De Prost, Dominique ^c   Vollot, Fabienne ^c   Dutrillaux, Fabienne ^c   Lorenzini, Jean Louis ^c   Lequerrec, Agnès ^c   Boinot, Catherine ^c   Freyburger, Geneviève ^c   Denninger, Marie Hélène ^c   more..

^a HÔPITAL SAINT ELOI   (France)

^b TIMONE HOSPITAL   (France)

^c NONE

Author keywords

ABO blood group; Factor V Leiden homozygotes; Methylene tetrahydrofolate reductase; Venous thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; LEUCINE; PROTEIN C; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; VALINE;

ADULT; ARTICLE; BLOOD GROUP ABO SYSTEM; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HAPLOTYPE; HEMOSTASIS; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VEIN THROMBOSIS;

ABO BLOOD-GROUP SYSTEM; ADULT; CASE-CONTROL STUDIES; FACTOR V; FACTOR XIII; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMOSTASIS; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ODDS RATIO; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROTEIN C; PROTHROMBIN; RETROSPECTIVE STUDIES; RISK; VENOUS THROMBOSIS;

EID: 33750570455     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06353.x     Document Type: Article

References (27)

1. Almawi, W.Y., Tamim, H., Kreidy, R., Timson, G., Rahal, E., Nabulsi, M., Finan, R. & Irani-Hakime, N. (2005) A case control study on the contribution of factor V-Leiden, prothrombin G20210A and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. Journal of Thrombosis and Thrombolysis, 19, 189-196.
2. Canavy, I., Henry, M., Morange, P.E., Tiret, L., Poirier, O., Ebagosti, A., Borg, M. & Juhan-Vague, I. (2000) Genetic polymorphisms and coronary artery disease in the south of France. Thrombosis and Haemostasis, 83, 212-216.
3. Catto, A.J., Kohler, H.P., Coore, J., Mansfield, M.W., Stickland, M.H. & Grant, P.J. (1999) Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood, 93, 906-908.
4. De Stefano, V., Casorelli, I., Rossi, E., Zappacosta, B. & Leone, G (2000) Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Seminars in Thrombosis and Haemostasis, 26, 305-311.
5. Den Heijer, M., Lewington, S. & Clarke, R. (2005) Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. Journal of Thrombosis and Haemostasis, 3, 292-299.
6. Ehrenforth, S., Nemes, L., Mannhalter, C., Rosendaal, F., Koder, S., Zoghlami-Rintelen, C., Scharrer, I. & Pabinger, I. (2004) Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. Journal of Thrombosis and Haemostasis, 2, 430-436.
7. Emmerich, J., Alhenc-Gelas, M., Aillaud, M.F., Juhan-Vague, I., Jude, B., Garcin, J.M., Dreyfus, M., de Moerloose, P., Le Querrec, A., Priollet, P., Berruyer, M., Vallantin, X., Wolf, M., Aiach, M. & Fiessinger, J.N. (1997) Clinical features in 36 patients homozygous for the ARG506 GLN factor V mutation. Thrombosis and Haemostasis, 77, 620-623.
8. Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G., Boers, G.J., den Heijer, M., Kluijtmans, L.A.J., den Heuvel, L.P. & Rozen, R. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolatereductase. Nature Genetics, 10, 111-113.
9. Greengard, J.S., Eichinger, S., Griffin, J.H. & Bauer, K.A. (1994) Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg Gln mutation in the gene for factor V. New England Journal of Medicine, 331, 1559-1562
10. Henry, M., Tregouet, D.A., Alessi, M.C., Aillaud, M.F., Visvikis, S., Siest, G., Tiret, L. & Juhan-Vague, I. (1998) Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort Arteriosclerosis. Thrombosis Vascular Biology, 18, 84-91.
11. Henry, M., Aubert, H., Morange, P.E., Nanni, I., Alessi, M.C., Tiret, L. & Juhan-Vague, I. (2001) Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood, 97, 2053-2058.
12. Juul, K., Tybjaerg-Hansen, A., Schnohr, P. & Nordestgaard, B.G. (2004) Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Annals of Internal Medicine, 140, 330-337.
13. Keijzer, M.B., den Heijer, M., Blom, H.J., Bos, G.M., Willems, HP, Gerrits, W.B. & Rosendaal, F.R. (2002) Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolate-reductase (MTHFR) and inherited thrombophilic factors in venous thromboembolism. Thrombosis and Haemostasis, 88, 723-728.
14. Lane, D.A. & Molica, L.R (2002) Haemostatic gene polymorphisms in venous and arterial thrombosis. Pathophysiology of Haemostasis and Thrombosis, 32, 213-215.
15. Le Cam-Duchez, V., Gandrille, S., Tregouet, D., Alhenc-Gelas, M., Emmerich, J., Fiessinger, J.N., Borg, J.Y. & Aiach, M. (1999) Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation. British Journal of Haematology, 106, 889-897.
16. Morelli, V.M., De Visser, M.C.H., Vos, H.L., Bertina, R.M. & Rosendaal, F.R. (2005) ABO blood group genotypes and the risk of venous thrombosis: affect of factor V Leiden. Journal of Thrombosis and Haemostasis, 3, 183-185.
17. Poort, S.R., Rosendaal, F.R., Reitsma, P.H. & Bertina, R.M. (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88, 3698-3703.
18. Procare group (2000) Comparison of the thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: retrospective analysis from the Procare Study. Blood Coagulation and Fibrinolysis, 11, 511-518.
19. Procare group (2004) Risk of venous thromboembolism during pregnancy in homozygous carriers of the factor V Leiden mutation: are there any predictive factors? Journal of Thrombosis and Haemostasis, 2, 359-360.
20. Rintelen, C., Mannhalter, C., Ireland, H., Lane, D.A., Knöbl, P., Lechner, K. & Pabinger, I. (1996) Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for the factor V Leiden. British Journal of Haematology, 93, 487-490.
21. Robert, A., Aillaud, M.F., Eschwege, V., Rabdrianjohany, A., Scarabin, Y. & Juhan-Vague, I. (2000) ABO blood group genotypes and the risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thrombosis and Haemostasis, 83, 630-631.
22. Rosendaal, F.R., Koster, T., Vandenbroucke, J.P. & Bertina, R.M. (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated Protein C resistance). Blood, 85, 1504-1508.
23. Samama, M.M., Trossaërt, M., Horellou, M.H., Elalamy, I. & Conard, J. (1995) Risk of thrombosis in patients homozygous for factor V Leiden. Blood, 86, 4700-4702
24. Schneider, M., Nagashima, M., Knappe, S., Zhao, L., Morser, J. & Nsheim, M. (2002) Amino acid residues in the P6-P'3 region of thrombin activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. Journal of Biological Chemistry, 277, 9944-9951.
25. Spek, C.A., Koster, T., Rosendaal, F.R., Bertina, R.M. & Reitsma, P.H. (1995) Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and antithrombic risk. Arteriosclerosis, Thrombosis, Vascular Biology, 15, 214-218.
26. Tirado, I., Mateo, J., Soria, J.M., Oliver, A., Martinez-Sanchez, E., Vallve, C., Borrel, M, Urrutia, T & Fontcuberta, J. (2005) The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thrombosis and Haemostasis, 93, 468-474.
27. Tosseto, A., Missiaglia, E., Gatto, E. & Rodighiero, F. (1997) The VITA project: C677T mutation in the methylene-tetrahydrofolate reductase gene and the risk of venous thromboembolism. British Journal of Haematology, 97, 804-806.